EP4673147A1 — Manufacturing of bupivacaine multivesicular liposomes
Assigned to Pacira Pharmaceuticals Inc · Expires 2026-01-07 · 0y expired
What this patent protects
The present disclosure relates to a new and improved large scale commercial manufacturing process of making bupivacaine multivesicular liposomes (MVLs) comprising DPEC, DPPG, cholesterol and tricaprylin. Batches of bupivacaine MVLs prepared by the new process have high yields, im…
USPTO Abstract
The present disclosure relates to a new and improved large scale commercial manufacturing process of making bupivacaine multivesicular liposomes (MVLs) comprising DPEC, DPPG, cholesterol and tricaprylin. Batches of bupivacaine MVLs prepared by the new process have high yields, improved stability profiles, and desired particle size distributions.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.